CrushSCI.com
90.2Average days
79Median days
6Fastest days
258Longest days
422025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

108 days

A simple and convenient method for the purification of Haemophilus Influenzae type b polysaccharide PRP

Authors
Darshan Gandhi; Rahul Patil; Manoj Joshi; Sunil Goel; Rajeev Dhere; Cyrus Poonawalla; Suresh BeriShow moreShow less
Affiliations
Serum Institute of India Pvt. Ltd., Pune, IndiaShow moreShow less
Source PDF DOI Publisher page
9 days

From discovery to innovation in animal health: meeting report of the second DIAH conference

Authors
Johannes Charlier; Laetitia Cicchelero; Beatrice Vos; Juerg Baggenstoss; Hervé Poulet; Dieter Vancraeynest; Sven ArnoutsShow moreShow less
Affiliations
Kreavet BV, Hendrik Mertensstraat 17, Kruibeke, 9150, Belgium; Ghent University, Salisburylaan 133, Merelbeke, 9820, Belgium; Stonehaven Cozmix Group, Schlossmühlestrasse 9, Frauenfeld, 8500, Switzerland; Boehringer-Ingelheim, 29 Avenue Tony Garnier, Lyon, 69007, France; Zoetis, Mercuriusstraat 20, Zaventem, 1930, BelgiumShow moreShow less
Source PDF DOI Publisher page
11 days

Assessing consequences of maternal immunization on fetal outcomes - A meeting report

Authors
Stephen Evans; Flor M. Munoz; Steve Black; Kathryn M. Edwards; Nick J. Andrews; Benjamin Atkins; Madhava Ram Balakrishnan; Marco Cavaleri; Hannah G. Davies; Alemayehu Duga; Janet A. Englund; Deshayne B. Fell; Delyth Jones; Kirsty Le Doare; Gwen Lemey; Shabir Madhi; Souad Mansouri; Solange Milolo Tshilumba; Jezid Miranda; Paulina Morales-Ruiz; Victoria Prudence Nambasa; Hanna Nohynek; Julien Nyombayire; Lidia Oostvogels; David Radley; Annette Regan; Anna C. Seale; Katerina Rok Song; James Southern; Jens-Ulrich Stegmann; Marc Baay; Pieter Neels; Frank VandendriesscheShow moreShow less
Affiliations
International Alliance of Biological Standardisation, Geneva, Switzerland; Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Global Vaccine Data Network Uniservices, Auckland, 1010, New Zealand; Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK; Department Epidemiology Informatics, Murdoch Children's Research Institute, Parkville, Victoria, 3052, Australia; Pharmacovigilance Unit, World Health Organization, Geneva, Switzerland; EMA, Amsterdam, Netherlands; Centre for Neonatal and Paediatric Infection, City St George's, University of London, London, UK; London School of Hygiene & Tropical Medicine, London, UK; Department for Infection and Population Health, Institute for Global Health, University College London, UK; Africa Centres for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia; Seattle Children's Research Institute and Department of Pediatrics, University of Washington, 4800 Sand Point Way NE, Seattle, WA, 98105, USA; Medical Evidence Development, Pfizer Inc., New York, USA; GSK, Stevenage, UK; Makerere University Johns Hopkins Research Collaboration (MUJHU), Kampala, Uganda; Global Health Institute (GHI), University of Antwerp, Antwerp, Belgium; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; BioNet, 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok, 10260, Thailand; Clinical Research and Immunization, Department of Tropical Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo; Department of Obstetrics and Gynecology, Faculty of Medicine, University of Cartagena, Zaragocilla Carrera 50 #24-63, Cartagena de Indias, 130014, Colombia; African Union Development Agency-NEPAD, Johannesburg, South Africa; Finnish Institute for Health and Welfare, Helsinki, Finland; Center for Family Health Research, P.O. Box 780, Kigali, Rwanda; MinervaX ApS, Frederiksberg, Denmark; Pfizer Vaccines, Pfizer Inc., Pearl River, NY, USA; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, 91101, USA; School of Nursing and Health Professions, University of San Francisco, Orange, CA, 92686, USA; Global Health Division, Gates Foundation, Seattle, USA; International Vaccine Institute, Seoul, Republic of Korea; South African Health Products Regulatory Authority (SAPHRA), Gauteng, South Africa; GSK, Wavre, Belgium; P95 Clinical & Epidemiology Services, Leuven, BelgiumShow moreShow less
Source PDF DOI Publisher page
13 days

Globally harmonized specifications: Implementing a patient-centric, enhanced control strategy – a meeting report

Authors
Yoji Sato; Andrew Chang; Cristiana Campa; Robin Levis; Masayo Takahashi; Phil Krause; Akiko Ishii-Watabe; Takahiro Yamaguchi; Horacio Pappa; Keiko Funato; Bénédicte Mouterde; Patrice Riou; Gerald Gellermann; Marisa K. Joubert; Vanessa Auquier; Jayda Siggers; Emmanuelle Charton; Anuradha Gupta; Minkyung Kim; Hiroko Shibata; Sirichair Krabesri; Sasiwimon Patasema; Jayoung Kim; Daisy Nie; Kaushik Sarkar; Shin Kawamata; Kok-Yew Ngew; Dean Smith; Shawn NovickShow moreShow less
Affiliations
National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki Ward, Kawasaki, Kanagawa, 210-9501, Japan; Novo Nordisk, 800 Scudders Mill Road Plainsboro, NJ, 08536, USA; GSK, Viale Dell'Agricoltura, 7, Verona, VR, 37135, Italy; Center for Biologics Evaluation and Research of the US Food and Drug Administration, 1401 Rockville Pike, Suite 200N/HFM-47, Rockville, MD, 20852-1448, USA; Riken Center for Developmental Biology, 2-2-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan; Asahi Kasei Pharma Corporation, 632-1, Izunokuni, Shizuoka, 410-2321, Japan; United States Pharmacopeia, 12601 Twinbrook Pkwy, Rockville, MD, 20852-1717, USA; GlaxoSmithKline, Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo, 107-0052, Japan; Sanofi, 1541, Avenue Marcel Merieux, Marcy L’Etoile, 69280, France; Novartis Pharma Services AG, Lichtstrasse 35, Basel, CH-4056, Switzerland; Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, 91320, USA; Union Chimique Belge, Allée de La Recherche, Brussels, 60 1070, Belgium; Health Canada, 1801B, Ottawa, Ontario, K1A 0K9, Canada; European Directorate for the Quality of Medicines & HealthCare, 7 Allée Kastner, CS 30026, Strasbourg, F-67081, France; Indian Pharmacopoeia Commission, Sector 23, Raj Nagar Ghaziabad, Uttar Pradesh, 201002, India; Thai Pharmacopeia, Institute of Thai Traditional Medicine, Department of Thai Traditional and Alternative Medicine, Ministry of Public Health, Nonthaburi, 11000, Thailand; Korean Pharmacopeia, 187, Osongsaengmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea; Novartis Pharmaceuticals Corporation, 1 Health Plz, East Hanover, NJ, 07936, USA; Novo Nordisk A/S, Novo Allé, Bagsvaerd, 2880, Denmark; Cyto-Facto, Shimin Byoin Mae Bldg 3F, 2-1-11 Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan; P95 Epidemiology and Pharmacovigilance, Koning Leopold III Laan 1, Leuven, 3001, Belgium; IABS, Rue de L’Est 8, Geneva, CH-1207, SwitzerlandShow moreShow less
Source PDF DOI Publisher page
258 days

Development and validation of a quantitative real-time PCR method for determination of residual host DNA in recombinant human C1 esterase inhibitor (rhC1INH)

Authors
Cong Cong; Xiaoping Yu; Tianfei Du; Yali Gao; Jiayao Tian; Chunyang Li; Lanjun LiuShow moreShow less
Affiliations
Chengdu Institute of Biological Products Co.,Ltd, Chengdu, Sichuan Province, 610023, ChinaShow moreShow less
Source PDF DOI Publisher page
94 days

Supporting 3Rs approaches in biologicals testing: responses from a survey of Manufacturers, Contract Research Organisations, National Control Laboratories and National Regulatory Authorities

Authors
Elliot Lilley; Sunil Goel; Robin Levis; Shajahan Shaid; Sarah Sheridan; Paul Stickings; Laura Viviani; Anthony HolmesShow moreShow less
Affiliations
NC3Rs, London, United Kingdom; Serum Institute of India, India; Food and Drug Administration, USA; GlaxoSmithKline, Germany; Merck, Glasgow, United Kingdom; Medicines and Healthcare Products Regulatory Agency, United Kingdom; SciEthiq, ItalyShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does BIOLOGICALS take to review a manuscript?

As of 2026-11-19, CrushSCI has 15 complete review records for BIOLOGICALS. The fastest paper went from submission to acceptance in 6 days (Report of the international conference on animal testing replacement for vaccines: A one health view on global outlook and future strategy, received 2026-07-15, accepted 2026-07-21); the slowest took 258 days. The average is 90.2 days and the median is 79 days. The fastest record has an unusually short interval; please check the original source.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.